Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Lab services company Charles River Laboratories (NYSE:CRL)
will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight from Equal Weight and raised its price target.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
